DexComXSWX:DXCM 90 Net Current Asset Value is CHF1.34 as of Mar. 2026, which is 100% below its 10-year median of 44.25. GuruFocus rates XSWX:DXCM with a GF Score™ of 90/100 and a GF Value™ of CHF85.31. The stock has 3 warning signs investors should review. Among 567 Medical Devices & Instruments companies, DexCom ranks worse than 93.47% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
DexCom's net current asset value per share for the quarter that ended in Mar. 2026 was CHF1.34.
The historical rank and industry rank for DexCom's Net Current Asset Value or its related term are showing as below:
XSWX:DXCM'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 18.26 Med: 44.25 Max: 379.39
Current: 40.39
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of DexCom was 379.39. The lowest was 18.26. And the median was 44.25.
XSWX:DXCM's Price-to-Net-Current-Asset-Value is ranked worse than 93.47% of 567
companies
in the Medical Devices & Instruments industry
Industry Median: 4.98
vs XSWX:DXCM: 40.39
DexCom (XSWX:DXCM) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
DexCom Net Current Asset Value Related Terms
DexCom Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for DexCom's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:DXCM vs GEHC, STE, ZBH: Net Current Asset Value Comparison
For the Medical Devices subindustry, DexCom's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexCom Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where DexCom's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of CHF1.34 mean?
DexCom (XSWX:DXCM) has a Net Current Asset Value of CHF1.34 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on DexCom and its competitors. This is 97% below median its historical median of 44.25. Over the past decade, DexCom's Net Current Asset Value has ranged from 18.26 to 379.39. According to the industry distribution chart, DexCom ranks #530 out of 567 companies in the Medical Devices & Instruments industry, placing it in the top 93.5%.
Is DexCom's Net Current Asset Value too high?
DexCom's current Net Current Asset Value of CHF1.34 is 97% below median its 10-year median of 44.25. Over the past 10 years, this metric has ranged from a low of 18.26 to a high of 379.39. Based on the distribution chart, DexCom ranks #530 out of 567 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, DexCom has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does DexCom's Net Current Asset Value compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #530 out of 567 companies for Net Current Asset Value. This places DexCom in the lower half of its industry. The industry median Net Current Asset Value is 4.98. Historically, DexCom's own Net Current Asset Value has ranged from 18.26 to 379.39 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.98, based on 567 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on DexCom and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexCom's current Net Current Asset Value is CHF1.34, which is 97% below median its own 10-year median of 44.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
DexCom (XSWX:DXCM) has a current Net Current Asset Value of CHF1.34. The stock's GF Value™ is CHF85.31, compared to a current price of CHF56.54 — trading 33.7% below its estimated fair value. The current Net Current Asset Value is CHF1.34, which is 97% below median its 10-year median of 44.25. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For DexCom (XSWX:DXCM), the current Net Current Asset Value is CHF1.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DexCom (XSWX:DXCM) Overvalued in 2026?
Based on GuruFocus' analysis, DexCom stock appears to be undervalued.
The current stock price of CHF56.54 is trading 33.7% below its estimated GF Value™ of CHF85.31.
Key valuation signals for XSWX:DXCM:
Net Current Asset Value: CHF1.34 (97% below median its 10-year median of 44.25)
GF Value™: CHF85.31 vs. price of CHF56.54 (33.7% below fair value)
No single metric tells the full story. See the XSWX:DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score
Get the complete analysis for XSWX:DXCM
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DXCM has been successfully added to your 
